Mitochondrial profiling of acute myeloid leukemia in the assessment of response to apoptosis modulating drugs

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Ishizawa, Jo ^a   Kojima, Kensuke ^a,d   McQueen, Teresa ^a   Ruvolo, Vivian ^a   Chachad, Dhruv ^a   Nogueras Gonzalez, Graciela M ^a   Huang, Xuelin ^a   Pierceall, William E ^b   Dettman, E J ^b   Cardone, Michael H ^b   Shacham, Sharon ^c   Konopleva, Marina ^a   Andreeff, Michael ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Eutropics Pharmaceuticals   (United States)

^c Karyopharm Therapeutics   (United States)

^d SAGA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; CYTARABINE; NUTLIN 3; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; SELINEXOR; VENETOCLAX; ANTINEOPLASTIC AGENT; BAX PROTEIN (53-86); MCL1 PROTEIN, HUMAN; ONCOPROTEIN; PEPTIDE FRAGMENT;

ACUTE MYELOBLASTIC LEUKEMIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; MITOCHONDRION; MOUSE; MYELOID LEUKEMIA CELL LINE; NONHUMAN; PREDICTION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; LEUKEMIA, MYELOID, ACUTE; METABOLISM; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MITOCHONDRIA; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 84945563190     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138377     Document Type: Review

References (26)

1. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014; 15(1):49-63. doi: 10.1038/nrm3722 PMID: 24355989
2. Deng J, Carlson N, Takeyama K, Dal Cin P, Shipp M, Letai A. BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. Cancer Cell. 2007; 12(2):171-85. PMID: 17692808
3. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, et al. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell. 2012; 151(2):344-55. doi: 10.1016/j.cell.2012.08.038 PMID: 23063124
4. Ni Chonghaile T, Sarosiek KA, Vo TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011; 334-(6059):1129-33. doi: 10.1126/science.1206727 PMID: 22033517
5. Ryan J, Letai A. BH3 profiling in whole cells by fluorimeter or FACS. Methods. 2013; 61(2):156-64. doi: 10.1016/j.ymeth.2013.04.006 PMID: 23607990
6. Pierceall WE, Kornblau SM, Carlson NE, Huang X, Blake N, Lena R, et al. BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia. Mol Cancer Ther. 2013; 12-(12):2940-9. doi: 10.1158/1535-7163.MCT-13-0692 PMID: 24092807
7. Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, et al. Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. Cancer Discov. 2014; 4(3):362-75. doi: 10. 1158/2159-8290.CD-13-0609 PMID: 24346116
8. Pierceall WE, Lena RJ, Medeiros BC, Blake N, Doykan C, Elashoff M, et al. Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. Leuk Res. 2014; 38 (5):564-8. doi: 10.1016/j.leukres.2014.02.007 PMID: 24636337
9. Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia. 2014; 28(8):1657-65. doi: 10.1038/leu.2014.44 PMID: 24451410
10. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, et al. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell. 2006; 10(5):375-88. PMID: 17097560
11. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013; 19-(2):202-8. doi: 10.1038/nm.3048 PMID: 23291630
12. Kojima K, Konopleva M, Samudio IJ, Shikami M, Cabreira-Hansen M, McQueen T, et al. MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. Blood. 2005; 106-(9):3150-9. PMID: 16014563
13. Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, et al. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood. 2013; 121(20):4166-74. doi: 10.1182/blood-2012-08-447581 PMID: 23564911
14. Long J, Parkin B, Ouillette P, Bixby D, Shedden K, Erba H, et al. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Blood. 2010; 116(1):71-80. doi: 10.1182/blood-2010-01-261628 PMID: 20404136
15. Ryan JA, Brunelle JK, Letai A. Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107(29):12895-900. doi: 10.1073/pnas.0914878107 PMID: 20615979
16. Konopleva M, Pollyea DA, Potluri J, Chyla BJ, Busman T, McKeegan E, et al. A phase 2 study of ABT-199 (GDC-0199) in patients with acute myelogenous leukemia (AML). Blood. 2014;abstr:118.
17. Andreeff M, Kojima K, Ruvolo V, Younes A, Wei W, Konopleva M, et al. Pharmacodynamic biomarkers in the phase 1 trial of RG7112, a small-molecule MDM2 antagonist in leukemia Blood. 2011;abstr:1545.
18. Mau-Soerensen M, Razak ARA, Mahipal A, Mahaseth H, Gerecitano JF, Shacham S, et al. Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort. J Clin Oncol. 2014;suppl 3: :abstr 482.
19. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell. 2006; 9(5):351-65. PMID: 16697956
20. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Molecular cell. 2005; 17(3):393-403. PMID: 15694340
21. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Molecular cell. 2005; 17(4):525-35. PMID: 15721256
22. Chonghaile TN, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, et al. Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199. Cancer Discov. 2014; 4(9):1074-87. doi: 10.1158/2159-8290.CD-14-0353 PMID: 24994123
23. Kojima K, Konopleva M, Tsao T, Andreeff M, Ishida H, Shiotsu Y, et al. Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. Leukemia. 2010; 24(1):33-43. doi: 10.1038/leu.2009.212 PMID: 19946262
24. Seymour JF, Davids MS, Pagel JM, Kahl BS, Wierda WG, Puvvada S, et al. ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete response rate and durable disease control. J Clin Oncol. 2014; 32:5s, suppl:abstr 7015.
25. Kojima K, Konopleva M, Samudio IJ, Schober WD, Bornmann WG, Andreeff M. Concomitant inhibition of MDM2 and Bcl-2 protein function synergistically induce mitochondrial apoptosis in AML. Cell cycle. 2006; 5(23):2778-86. PMID: 17172851
26. Pan R, Kojima K, Zheng Z, Ruvolo VR, Nichols G, Leverson JD, et al. Activation of p53 by novel MDM2 antagonist RG7388 overcomes AML inherent and acquired resistance to Bcl-2 inhibitor ABT-199 (GDC-0199). Blood. 2014;abstr:2162.